Top Page
BriaCell Therapeutics
(TSX:BCT)
BriaCell Therapeutics (BCT) vs. iShares MSCI Canada ETF (EWC)
BriaCell Therapeutics Business Overview & Revenue Model
BriaCell Therapeutics Financial Statement Overview
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -73.62K | -147.89K | -114.04K | -20.49K | -19.39K | -19.44K |
| EBITDA | -36.00M | -36.63M | -45.91K | -27.23M | -34.05M | -6.95M |
| Net Income | -42.07M | -36.50M | -6.62K | -20.30M | -11.58M | -2.90M |
Balance Sheet | ||||||
| Total Assets | 13.08M | 21.65M | 5.87M | 27.16M | 42.58M | 58.04M |
| Cash, Cash Equivalents and Short-Term Investments | 10.18M | 17.87M | 862.09K | 21.25M | 41.04M | 57.27M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.99K |
| Total Liabilities | 3.72M | 4.32M | 8.56M | 30.94M | 32.25M | 782.24K |
| Stockholders Equity | 9.98M | 24.72M | -2.38M | -3.78M | 10.33M | 57.26M |
Cash Flow | ||||||
| Free Cash Flow | -31.91M | -28.17M | -24.58M | -23.74M | -12.48M | -7.75M |
| Operating Cash Flow | -31.91M | -28.17M | -24.13M | -23.74M | -12.48M | -7.75M |
| Investing Cash Flow | -7.68M | -7.65M | -681.80K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 33.49M | 45.45M | 4.42M | 3.95M | -3.74M | 65.00M |
BriaCell Therapeutics Technical Analysis
BriaCell Therapeutics Risk Analysis
BriaCell Therapeutics Peers Comparison
BriaCell Therapeutics Corporate Events
BriaCell Therapeutics and its majority-owned subsidiary BriaPro Therapeutics have signed a definitive asset purchase agreement under which BriaPro will acquire BriaCell’s exclusive license to develop and commercialize the Soluble CD80 biologic for cancer treatment, along with related assets. BriaPro will hold worldwide development and commercialization rights and pay UMBC a 2% royalty on future product sales, while BriaCell will provide up to $3 million in research funding via a credit facility and receive nearly 24 million BriaPro shares, raising its ownership to about 78% pending minority shareholder approval and an independent valuation, reflecting a strategic bid to accelerate development of the potentially transformational anti-cancer agent and integrate it with BriaCell’s broader immunotherapy portfolio.
The most recent analyst rating on (TSE:BCT) stock is a Hold with a C$5.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
BriaCell Therapeutics has received a fifth consecutive positive recommendation from an independent Data Safety Monitoring Board for its pivotal Phase 3 Bria-ABC study evaluating Bria-IMT in combination with an immune checkpoint inhibitor in metastatic breast cancer. The board reported no safety concerns and advised the trial to continue unchanged, reinforcing the regimen’s favorable safety profile.
The Phase 3 trial is being conducted under U.S. FDA Fast Track designation, underscoring the significant unmet medical need in metastatic breast cancer and potentially accelerating the path toward regulatory review if efficacy is confirmed. The continued clean safety reviews support BriaCell’s strategy of advancing Bria-IMT as a potential new immunotherapy option, which could strengthen the company’s position in the competitive oncology space and carries implications for patients, clinicians, and investors following late-stage cancer programs.
The most recent analyst rating on (TSE:BCT) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
BriaCell Therapeutics has released new imaging data from its Phase 2 study of Bria-IMT in heavily pre-treated metastatic breast cancer patients, showing regression and resolution of metastatic lesions in the eye orbit, temporal lobe of the brain, liver, and spine, as well as evidence of robust CD8+ T-cell activation and tumor infiltration. Among the 54 patients treated with the Bria-IMT regimen plus a checkpoint inhibitor, no treatment-related discontinuations have been reported to date, and several patients with extensive prior therapy remain alive beyond two years, underscoring the potential durability and safety of Bria-IMT as it progresses into a pivotal Phase 3 trial and potentially strengthens BriaCell’s position in the immuno-oncology landscape.
The most recent analyst rating on (TSE:BCT) stock is a Hold with a C$6.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
BriaCell Therapeutics reported updated Phase 2 data for its Bria-IMT immunotherapy regimen in metastatic breast cancer, showing that 9 of 25 patients treated since 2022 remain alive more than 18 to 47 months after enrollment, markedly exceeding survival benchmarks reported for standard-of-care therapies in comparable late-stage populations. The company highlighted detailed cases of heavily pretreated women, including patients previously exposed to antibody-drug conjugates such as Enhertu and Trodelvy, who achieved prolonged survival and, in some instances, significant disease control without Bria-IMT–related treatment discontinuations. Comparative analyses suggest that Bria-IMT plus checkpoint inhibitor therapy may deliver higher one- and two-year survival rates than several referenced regimens, supporting BriaCell’s view that its approach could address a substantial unmet need in metastatic breast cancer and reinforcing the strategic importance of its ongoing pivotal Phase 3 trial, which is designed to confirm overall survival benefits and potentially reposition the company within the competitive oncology landscape.
The most recent analyst rating on (TSE:BCT) stock is a Hold with a C$6.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
BriaCell Therapeutics has priced a best-efforts public offering of 5,366,726 units, each comprising one common share or pre-funded warrant and one warrant, at $5.59 per unit for expected gross proceeds of approximately $30 million before fees and expenses. The warrants, exercisable at $6.93 per share for five years, have been approved for listing on the Nasdaq Capital Market under the symbol BCTXL starting January 14, 2026, with the offering slated to close on January 15, 2026, subject to customary conditions; BriaCell plans to use the net proceeds to support working capital, general corporate purposes and advancement of its business objectives, reinforcing its funding base as it progresses its immunotherapy pipeline.
The most recent analyst rating on (TSE:BCT) stock is a Sell with a C$9.50 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
BriaCell Therapeutics reported an 11‑month sustained complete resolution of a lung metastasis in a 78‑year‑old patient with hormone receptor–positive, HER2‑negative metastatic breast cancer treated with its personalized off‑the‑shelf immunotherapy Bria‑OTS in a Phase 1/2a study. The patient, who had failed multiple prior treatments, showed 100% disappearance of a lung tumor after four doses of Bria‑OTS monotherapy, with the response repeatedly confirmed over nearly a year, no treatment‑limiting toxicities observed, and stable disease at other evaluable sites; BriaCell has completed the Phase 1 dose escalation and is now advancing the Phase 2a dose‑expansion stage combining Bria‑OTS with an immune checkpoint inhibitor, a step that could strengthen its position in the metastatic breast cancer treatment landscape and underscore the platform’s potential safety and efficacy for patients with limited options.
The most recent analyst rating on (TSE:BCT) stock is a Sell with a C$9.50 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
BriaCell Therapeutics’ pivotal Phase 3 trial of its lead immunotherapy candidate Bria-IMT in metastatic breast cancer has been highlighted by Nature Medicine as one of the “clinical trials to watch in 2026,” underscoring rising scientific and clinical interest in the program. The BRIA-ABC study, which compares Bria-IMT plus an immune checkpoint inhibitor against physician’s choice therapy in a broad, real‑world metastatic breast cancer population, has screened more than 230 patients and enrolled over 160 to date, with top-line data expected as early as the first half of 2026 and an interim overall survival analysis planned after 144 events; positive results could support full regulatory approval and commercialization of Bria-IMT, potentially strengthening BriaCell’s position in the oncology immunotherapy market.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$40.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
BriaCell Therapeutics presented promising clinical data at the San Antonio Breast Cancer Symposium 2025, showcasing the potential of their Bria-IMT regimen in treating metastatic breast cancer. The Phase 3 study supports the use of biomarkers to identify patients who could benefit from the treatment, while Phase 2 data highlights significant long-term survival benefits. The findings suggest that Bria-IMT could provide a personalized therapeutic strategy for patients with limited treatment options, potentially impacting the company’s position in the oncology market.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$40.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
BriaCell Therapeutics has announced that its Phase 3 clinical study for its lead candidate, Bria-IMT, in combination with an immune checkpoint inhibitor, is progressing well with over 160 patients enrolled. The study, which targets metastatic breast cancer, is on track for a topline data readout in the first half of 2026, potentially leading to full approval and marketing authorization if results are positive.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$40.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.